

# **Europe Ovarian Cancer Diagnostics Market - Industry Trends and Forecast to 2030**

Market Report | 2022-11-01 | 145 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

### Report description:

The Europe ovarian cancer diagnostics market is projected to register a substantial CAGR of 6.5% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

## Market Segmentation:

Europe Ovarian Cancer Diagnostics Market- By Product Type (Instruments, Kits and Reagents), Procedure Type (Biopsy Test, Medical Imaging Test, Blood Markers Testing, Genetic Testing), Cancer Type (Germ Cell, Epithelial Tumor, Stromal Cell Tumor), End User (Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes, Others), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of Europe ovarian cancer diagnostics market are:

- Growing ovarian cancer awareness
- Improved diagnostic processes and techniques
- Increase in number of new cases every year
- Improved imaging techniques

# Market Players:

The major companies which are dealing in the Europe ovarian cancer diagnostics market are listed below:

- F. Hoffmann-la roche ltd
- Tosoh india pvt. Ltd.
- Luminex corporation
- Quest diagnostics incorporated
- Thermo fisher scientific Inc.
- Ngenebio
- Abbott
- Siemens healthcare private limited

Scotts International, EU Vat number: PL 6772247784

- Myriad genetics Inc.
- Bio-rad laboratories, Inc.
- R&d systems, Inc.
- Foundation medicine, Inc.
- Biosupply Itd
- Lcm genect srl
- Abcam plc.
- Monobind Inc.
- Fujirebio
- Mp biomedicals
- Biovision Inc.
- Boster biological technology
- Genway biotech
- Lifespan biosciences, Inc

### **Table of Contents:**

TABLE OF CONTENTS

- 1 INTRODUCTION 21
- 1.1 OBJECTIVES OF THE STUDY 21
- 1.2 MARKET DEFINITION 21
- 1.3 OVERVIEW OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET 21
- 1.4 LIMITATIONS 22
- 1.5 MARKETS COVERED 23
- 2 MARKET SEGMENTATION 25
- 2.1 MARKETS COVERED 25
- 2.2 GEOGRAPHICAL SCOPE 26
- 2.3 YEARS CONSIDERED FOR THE STUDY 27
- 2.4 CURRENCY AND PRICING 27
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
- 2.6 MULTIVARIATE MODELLING 31
- 2.7 PRODUCT TYPE LIFELINE CURVE 31
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
- 2.9 DBMR MARKET POSITION GRID 33
- 2.10 MARKET TESTING TYPE COVERAGE GRID 34
- 2.11 VENDOR SHARE ANALYSIS 35
- 2.12 SECONDARY SOURCES 36
- 2.13 ASSUMPTIONS 36
- 3 EXECUTIVE SUMMARY 37
- 4 PREMIUM INSIGHTS 40
- 4.1 PESTEL ANALYSIS 41
- 4.2 PORTER'S FIVE FORCES 42
- 4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 43
- 5 INDUSTRY INSIGHTS 44
- 5.1 CONCLUSION 45
- 6 REGULATIONS OF THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET 46

Scotts International. EU Vat number: PL 6772247784

#### 7 MARKET OVERVIEW 48

- **7.1 DRIVERS 50**
- 7.1.1 GROWING OVARIAN CANCER AWARENESS 50
- 7.1.2 IMPROVED DIAGNOSTIC PROCESSES AND TECHNIQUES 50
- 7.1.3 INCREASE IN NUMBER OF NEW CASES EVERY YEAR 51
- 7.1.4 IMPROVED IMAGING TECHNIQUES 51
- 7.2 RESTRAINS 52
- 7.2.1 HIGH COST OF DIAGNOSIS 52
- 7.2.2 ADVERSE EFFECTS OF THE TREATMENT 52
- 7.3 OPPORTUNITIES 53
- 7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 53
- 7.3.2 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS 53
- 7.4 CHALLENGES 54
- 7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
- 7.4.2 LACK OF SKILLED PROFESSIONALS 55
- 8 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 56
- 8.1 OVERVIEW 57
- 8.2 INSTRUMENTS 60
- 8.3 KITS AND REAGENTS 61
- 9 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE 62
- 9.1 OVERVIEW 63
- 9.2 BLOOD MARKERS TESTING 66
- 9.3 MEDICAL IMAGING TEST 67
- 9.4 BIOPSY TEST 68
- 9.5 GENETIC TESTING 69
- 10 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 70
- 10.1 OVERVIEW 71
- 10.2 EPITHELIAL TUMOR 74
- 10.3 GERM CELL 74
- 10.4 STROMAL CELL TUMOR 75
- 11 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER 76
- 11.1 OVERVIEW 77
- 11.2 CANCER DIAGNOSTIC CENTERS 80
- 11.3 HOSPITAL LABORATORIES 80
- 11.4 RESEARCH INSTITUTES 81
- 11.5 OTHERS 82
- 12 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY 83
- 12.1 EUROPE 84
- 12.1.1 GERMANY 90
- 12.1.2 FRANCE 91
- 12.1.3 U.K. 92
- 12.1.4 ITALY 93
- 12.1.5 SPAIN 94
- 12.1.6 RUSSIA 95
- 12.1.7 TURKEY 96
- 12.1.8 BELGIUM 97

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1.9 NETHERLANDS 98
- 12.1.10 SWITZERLAND 99
- 12.1.11 REST OF EUROPE 100
- 13 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 101
- 13.1 COMPANY SHARE ANALYSIS: EUROPE 101
- 14 SWOT ANALYSIS 102
- 15 COMPANY PROFILE 103
- 15.1 F. HOFFMANN-LA ROCHE LTD 103
- 15.1.1 COMPANY SNAPSHOT 103
- 15.1.2 REVENUE ANALYSIS 104
- 15.1.3 COMPANY SHARE ANALYSIS 104
- 15.1.4 PRODUCT PORTFOLIO 104
- 15.1.5 RECENT DEVELOPMENTS 105
- 15.2 TOSOH INDIA PVT. LTD. 106
- 15.2.1 COMPANY SNAPSHOT 106
- 15.2.2 COMPANY SHARE ANALYSIS 106
- 15.2.3 PRODUCT PORTFOLIO 107
- 15.2.4 RECENT DEVELOPMENT 107
- 15.3 LUMINEX CORPORATION (2022) 108
- 15.3.1 COMPANY SNAPSHOT 108
- 15.3.2 COMPANY SHARE ANALYSIS 108
- 15.3.3 PRODUCT PORTFOLIO 109
- 15.3.4 RECENT DEVELOPMENT 109
- 15.4 QUEST DIAGNOSTICS INCORPORATED (2022) 110
- 15.4.1 COMPANY SNAPSHOT 110
- 15.4.2 REVENUE ANALYSIS 110
- 15.4.3 COMPANY SHARE ANALYSIS 111
- 15.4.4 PRODUCT PORTFOLIO 111
- 15.4.5 RECENT DEVELOPMENTS 112
- 15.5 THERMO FISHER SCIENTIFIC INC 113
- 15.5.1 COMPANY SNAPSHOT 113
- 15.5.2 REVENUE ANALYSIS 113
- 15.5.3 COMPANY SHARE ANALYSIS 114
- 15.5.4 PRODUCT PORTFOLIO 114
- 15.5.5 RECENT DEVELOPMENT 114
- 15.6 ABBOTT 115
- 15.6.1 COMPANY SNAPSHOT 115
- 15.6.2 REVENUE ANALYSIS 116
- 15.6.3 PRODUCT PORTFOLIO 116
- 15.6.4 RECENT DEVELOPMENT 116
- 15.7 ABCAM PLC (2022) 117
- 15.7.1 COMPANY SNAPSHOT 117
- 15.7.2 REVENUE ANALYSIS 118
- 15.7.3 PRODUCT PORTFOLIO 118
- 15.7.4 1.7.4 RECENT DEVELOPMENT 118
- 15.8 BIOSUPPLY LTD 119
- 15.8.1 COMPANY SNAPSHOT 119

Scotts International. EU Vat number: PL 6772247784

- 15.8.2 PRODUCT PORTFOLIO 119
- 15.8.3 RECENT DEVELOPMENT 119
- 15.9 BIO-RADBIO LABORATORIES 120
- 15.9.1 COMPANY SNAPSHOT 120
- 15.9.2 REVENUE ANALYSIS 121
- 15.9.3 PRODUCT PORTFOLIO 121
- 15.9.4 RECENT DEVELOPMENTS 122
- 15.10 BIOVISION INC. 123
- 15.10.1 COMPANY SNAPSHOT 123
- 15.10.2 PRODUCT PORTFOLIO 123
- 15.10.3 RECENT DEVELOPMENT 123
- 15.11 BIOGENIX INC. PVT. LTD. 124
- 15.11.1 COMPANY SNAPSHOT 124
- 15.11.2 PRODUCT PORTFOLIO 124
- 15.11.3 RECENT DEVELOPMENT 124
- 15.12 BOSTER BIOLOGICAL TECHNOLOGY 125
- 15.12.1 COMPANY SNAPSHOT 125
- 15.12.2 PRODUCT PORTFOLIO 125
- 15.12.3 RECENT DEVELOPMENT 125
- 15.13 FOUNDATION MEDICINE 126
- 15.13.1 COMPANY SNAPSHOT 126
- 15.13.2 PRODUCT PORTFOLIO 126
- 15.13.3 RECENT DEVELOPMENT 126
- 15.14 FUJIREBIO 127
- 15.14.1 COMPANY SNAPSHOT 127
- 15.14.2 PRODUCT PORTFOLIO 127
- 15.14.3 RECENT DEVELOPMENT 127
- 15.15 GENWAY BIOTECH 128
- 15.15.1 COMPANY SNAPSHOT 128
- 15.15.2 PRODUCT PORTFOLIO 128
- 15.15.3 RECENT DEVELOPMENT 128
- 15.16 INEX INNOVATIVE PRIVATE LIMITED 129
- 15.16.1 COMPANY SNAPSHOT 129
- 15.16.2 PRODUCT PORTFOLIO 129
- 15.16.3 RECENT DEVELOPMENT 129
- 15.17 LCM GENETIC SRL 130
- 15.17.1 COMPANY SNAPSHOT 130
- 15.17.2 PRODUCT PORTFOLIO 130
- 15.17.3 RECENT DEVELOPMENT 130
- 15.18 LIFESPAN BIOSCIENCES, INC 131
- 15.18.1 COMPANY SNAPSHOT 131
- 15.18.2 PRODUCT PORTFOLIO 131
- 15.18.3 RECENT DEVELOPMENTS 132
- 15.19 MP BIOMEDICALS 133
- 15.19.1 COMPANY SNAPSHOT 133
- 15.19.2 PRODUCT PORTFOLIO 133
- 15.19.3 RECENT DEVELOPMENT 133

# Scotts International. EU Vat number: PL 6772247784

- 15.20 MONOBIND INC. 134
- 15.20.1 COMPANY SNAPSHOT 134
- 15.20.2 PRODUCT PORTFOLIO 134
- 15.20.3 RECENT DEVELOPMENT 134
- 15.21 MYRIAD GENETICS, INC. 135
- 15.21.1 COMPANY SNAPSHOT 135
- 15.21.2 REVENUE ANALYSIS 135
- 15.21.3 PRODUCT PORTFOLIO 136
- 15.21.4 RECENT DEVELOPMENT 136
- 15.22 NGENEBIO 137
- 15.22.1 COMPANY SNAPSHOT 137
- 15.22.2 PRODUCT PORTFOLIO 137
- 15.22.3 RECENT DEVELOPMENTS 138
- 15.23 R&D SYSTEMS, INC. 139
- 15.23.1 COMPANY SNAPSHOT 139
- 15.23.2 PRODUCT PORTFOLIO 139
- 15.23.3 RECENT DEVELOPMENT 139
- 15.24 SIEMENS MEDICAL SOLUTIONS 140
- 15.24.1 COMPANY SNAPSHOT 140
- 15.24.2 REVENUE ANALYSIS 140
- 15.24.3 PRODUCT PORTFOLIO 141
- 15.24.4 RECENT DEVELOPMENT 141
- 16 QUESTIONNAIRE 142
- 17 RELATED REPORTS 145



Print this form

To place an Order with Scotts International:

 $\hfill \Box$  - Complete the relevant blank fields and sign

# **Europe Ovarian Cancer Diagnostics Market - Industry Trends and Forecast to 2030**

Market Report | 2022-11-01 | 145 pages | Data Bridge Market Research

select license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
			VAT	
			Total	
	ant license option. For any questions ple at 23% for Polish based companies, indiv			
V/(I Will be daded (	te 25% for Folish bused companies, mark	riduais una Eo basca c	companies who are unable to provide a	vana Eo va
mail*		Phone*		
irst Name*		Last Name*		
ob title*				
		EU Vat / Tax ID / NIP number*		
		EU Vat / Tax ID /	NIP number*	
Company Name*		EU Vat / Tax ID / City*	NIP number*	
Company Name* Address* Zip Code*			NIP number*	
Company Name*		City*	NIP number*  2025-05-12	
Company Name*		City* Country*		